Payment overview · 2025
General Payments
$103.69
5 reported records · 3 companies
Healthcare provider profile · identity verified
Michael Shane Richardson, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · NORMAN, OK · NPI 1225179849
Verified facts
What the public records show
CMS Open Payments records show Michael Shane Richardson, P.A. received $103.69 in general payments during 2025 across 5 reported records.
Sumitomo Pharma America, Inc. accounted for 70.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $73.19 | 70.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.56 | 16.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.94 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.69 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $73.19 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 131 |
| Gabapentin | Gabapentin | 372 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 112 |
| Losartan Potassium | Losartan Potassium | 296 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 88 |
| Lisinopril | Lisinopril | 259 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 70 |
| Meloxicam | Meloxicam | 204 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 57 |
| Montelukast Sodium | Montelukast Sodium | 172 | 56 |
| Carvedilol | Carvedilol | 162 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 52 |
| Metformin Hcl | Metformin Hcl | 156 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 33 |
| Pregabalin | Pregabalin | 121 | 25 |
| Prednisone | Prednisone | 120 | 69 |
| Potassium Chloride | Potassium Chloride | 118 | 36 |
| Furosemide | Furosemide | 117 | 34 |
| Omeprazole | Omeprazole | 117 | 41 |
| Azithromycin | Azithromycin | 108 | 68 |
| Alprazolam | Alprazolam | 99 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 26 |
| Trazodone Hcl | Trazodone Hcl | 88 | 29 |
| Alendronate Sodium | Alendronate Sodium | 87 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 24 |
| Jardiance | Empagliflozin | 78 | 23 |
| Tramadol Hcl | Tramadol Hcl | 78 | 20 |
| Celecoxib | Celecoxib | 76 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 37 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 23 |
| Eliquis | Apixaban | 71 | 21 |
| Allopurinol | Allopurinol | 66 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 24 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 20 |
| Glipizide | Glipizide | 55 | 22 |
| Naproxen | Naproxen | 54 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 20 |
| Ibuprofen | Ibuprofen | 53 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 49 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Sertraline Hcl | Sertraline Hcl | 43 | 20 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 42 | 13 |
| Ozempic | Semaglutide | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 12 |
| Simvastatin | Simvastatin | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 11 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.69 · 5 records | Sumitomo Pharma America, Inc. | AIRSUPRA, Cologuard Collection Kit, GEMTESA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error